nach oben

Neurocritical Care

Erschienen in:

30.09.2019 | Practical Pearl

Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone

verfasst von: Maximiliano A. Hawkes, Alejandro A. Hlavnicka, Nestor A. Wainsztein

Erschienen in: Neurocritical Care | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Reversible cerebral vasoconstriction syndrome (RCVS) causes reversible multifocal constriction of cerebral arteries. It is triggered by several conditions, including vasoactive medications, postpartum, migraine, hypertension, and arterial dissection [1]. Suspension of the precipitating agent, supportive care, and oral calcium channel blockers are the mainstay of treatment for most patients [2]. However, the development of refractory vasospasm, ischemic stroke, or intracerebral hemorrhage (ICH) may require further interventions, including intravenous (IV) or intra-arterial vasodilators and balloon angioplasty [2]. Yet, evidence for all these treatment options is weak and is based on case reports, case series, and expert’s opinion. We report a case of severe postpartum RVCS complicated by ICH successfully treated with IV milrinone infusion. …

Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11(10):906–17. https://doi.org/10.1016/S1474-4422(12)70135-7.CrossRefPubMed

Cappelen-Smith C, Calic Z, Cordato D. Reversible cerebral vasoconstriction syndrome: recognition and treatment. Curr Treat Options Neurol. 2017;19(6):21. https://doi.org/10.1007/s11940-017-0460-7.CrossRefPubMed

Purkayastha S, Sorond F. Transcranial Doppler ultrasound: technique and application. Semin Neurol. 2012;32(4):411–20. https://doi.org/10.1055/s-0032-1331812.CrossRefPubMed

Lazaridis C, Czosnyka M. Cerebral blood flow, brain tissue oxygen, and metabolic effects of decompressive craniectomy. Neurocrit Care. 2012;16(3):478–84. https://doi.org/10.1007/s12028-012-9685-1.CrossRefPubMed

Chen S-P, Fuh J-L, Wang S-J, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2009. https://doi.org/10.1002/ana.21951.CrossRefPubMedPubMedCentral

Ducros A, Hajj-Ali RA, Singhal AB, Wang S-J. Reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71(3):368. https://doi.org/10.1001/jamaneurol.2013.5875.CrossRefPubMed

Sattar A, Manousakis G, Jensen MB. Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther. 2010;8(10):1417–21. https://doi.org/10.1586/erc.10.124.CrossRefPubMedPubMedCentral

Sorensen DM. Reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2016;73(2):232–3. https://doi.org/10.1001/jamaneurol.2015.3472.CrossRefPubMed

Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology. 2017;88(3):228–36. https://doi.org/10.1212/WNL.0000000000003510.CrossRefPubMedPubMedCentral

10.

Singhal AB, Hajj-Ali RA, Topcuoglu MA, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011;68(8):1005–12. https://doi.org/10.1001/archneurol.2011.68.CrossRefPubMed

11.

Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser M-G. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101. https://doi.org/10.1093/brain/awm256.CrossRefPubMed

12.

Chen S-P, Fuh J-L, Lirng J-F, Chang F-C, Wang S-J. Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder? Neurology. 2006;67(12):2164–9. https://doi.org/10.1212/01.wnl.0000249115.63436.6d.CrossRefPubMed

13.

Marsh EB, Ziai WC, Llinas RH. The need for a rational approach to vasoconstrictive syndromes: transcranial doppler and calcium channel blockade in reversible cerebral vasoconstriction syndrome. Case Rep Neurol. 2016;8(2):161–71. https://doi.org/10.1159/000447626.CrossRefPubMedPubMedCentral

14.

Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34–44.CrossRefPubMed

15.

Katz BS, Fugate JE, Ameriso SF, et al. Clinical worsening in reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71(1):68–73. https://doi.org/10.1001/jamaneurol.2013.4639.CrossRefPubMed

16.

Elstner M, Linn J, Muller-Schunk S, Straube A. Reversible cerebral vasoconstriction syndrome: a complicated clinical course treated with intra-arterial application of nimodipine. Cephalalgia. 2009;29(6):677–82. https://doi.org/10.1111/j.1468-2982.2008.01768.x.CrossRefPubMed

17.

Linn J, Fesl G, Ottomeyer C, et al. Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a diagnostic tool in select cases? Cephalalgia. 2011;31(10):1074–81. https://doi.org/10.1177/0333102410394673.CrossRefPubMed

18.

Bouchard M, Verreault S, Gariepy J-L, Dupre N. Intra-arterial milrinone for reversible cerebral vasoconstriction syndrome. Headache. 2009;49(1):142–5. https://doi.org/10.1111/j.1526-4610.2008.01211.x.CrossRefPubMed

19.

Song JK, Fisher S, Seifert TD, et al. Postpartum cerebral angiopathy: atypical features and treatment with intracranial balloon angioplasty. Neuroradiology. 2004;46(12):1022–6. https://doi.org/10.1007/s00234-003-1129-3.CrossRefPubMed

20.

Al-Mufti F, Dodson V, Wajswol E, et al. Chemical angioplasty for medically refractory reversible cerebral vasoconstriction syndrome(). Br J Neurosurg. 2018;32(4):431–5. https://doi.org/10.1080/02688697.2018.1479512.CrossRefPubMed

21.

Fraticelli AT, Cholley BP, Losser M-R, Saint Maurice J-P, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(3):893–8. https://doi.org/10.1161/STROKEAHA.107.492447.CrossRefPubMed

22.

Lannes M, Teitelbaum J, del Pilar Cortes M, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16(3):354–62. https://doi.org/10.1007/s12028-012-9701-5.CrossRefPubMed

23.

Oyama N, Sakaguchi M, Higashida K, et al. Remarkable effect of a phosphodiesterase type 3 inhibitor, milrinone in a reversible cerebral vasoconstriction syndrome patient with ischemic stroke: a case report. J Neurol Sci. 2017;381:642. https://doi.org/10.1016/j.jns.2017.08.1808.CrossRef

24.

Lakhal K, Rodie-Talbere P-A, Alexandre P-L, Testard N, Rozec B, Daumas-Duport B. Continuous intravenous milrinone for severe reversible cerebral vasoconstriction syndrome (a case report). J Neurol Sci. 2019;397:55–7. https://doi.org/10.1016/j.jns.2018.12.027.CrossRefPubMed

Titel: Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone
verfasst von: Maximiliano A. Hawkes
Alejandro A. Hlavnicka
Nestor A. Wainsztein
Publikationsdatum: 30.09.2019
Verlag: Springer US
Erschienen in: Neurocritical Care / Ausgabe 1/2020
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-019-00850-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone

Excerpt

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Heart Rate Variability as a Biomarker of Neurocardiogenic Injury After Subarachnoid Hemorrhage

Autonomic Dysfunction in Guillain–Barré Syndrome Puts Patients at Risk

Worldwide Organization of Neurocritical Care: Results from the PRINCE Study Part 1

A Nail in The Brain: Delayed Traumatic Pseudoaneurysm

Palliative Care in the Neuro-ICU: Perceptions, Practice Patterns, and Preferences of Neurointensivists

Evidence for Mannitol as an Effective Agent Against Intracranial Hypertension: An Individual Patient Data Meta-analysis

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie